Clinical Trials Logo
  1. Home
  2. Primary CNS Lymphoma
  3. NCT04073147

Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma — VENOBI-CNS  

Primary CNS Lymphoma Clinical Trial

Official title:
Chemotherapy Free Treatment With Venetoclax and Obinutuzumab for Relapsed / Refractory Primary CNS Lymphoma Patients (VENOBI-CNS Study) - A Phase IB Study to Assess the Pharmacokinetics in the Cerebrospinal Fluid

Clinical Trial Summary

This is a phase IB study investigating the pharmacokinetics of the combination venetoclax and obinutuzumab in the cerebrospinal fluid of patient with relapsed primary CNS lymphoma.

Clinical Trial Description

This is a phase IB study investigating the pharmacokinetics of the combination venetoclax and obinutuzumab in the cerebrospinal fluid of patient with relapsed primary CNS lymphoma. Three dosing groups of venetoclax (600mg, 800mg, and 1000mg) are planned; dosing of obinutuzumab will be 1000mg for each dosing group. 15 patients are planned being included from two centers in Germany. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04073147
Study type Interventional
Source Klinikum Stuttgart
Contact
Status Terminated
Phase Phase 1
Start date May 12, 2020
Completion date November 25, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05036564 - Diagnosis; Objective RespOnse; THErApy N/A
Recruiting NCT03569995 - [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma Phase 2
Recruiting NCT04627753 - Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. Phase 2
Recruiting NCT05518383 - B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 Phase 4
Recruiting NCT05425654 - RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL Phase 2
Active, not recruiting NCT04443829 - Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma Phase 1
Recruiting NCT04006561 - Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost
Recruiting NCT04656431 - Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma Phase 1
Active, not recruiting NCT04464200 - 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers Phase 1
Recruiting NCT02934204 - Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma Phase 2
Recruiting NCT04947319 - Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Phase 2
Active, not recruiting NCT04134117 - Tisagenlecleucel In Primary CNS Lymphoma Phase 1
Withdrawn NCT03212807 - Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL Phase 2